Recent studies in the United States have shown great promise in the use of the polymerase chain reaction (PCR) to detect high-risk human papillomavirus DNA (HPV hr ) in order to triage specimens with diagnoses of atypical squamous cells of undetermined significance (ASCUS).
1,2 The technique has been suggested as a quality assurance device. [3] [4] [5] The utility of this technique for developing nations has not been fully assessed. Dutch groups have shown that persistent infection with HPV hr is necessary for the development and maintenance of high-grade squamous intraepithelial lesion (SIL). 6 PCR testing of Surinamese cervical scrapings by Dutch groups has been performed and reported as a viable technique. 7 Surinam has five times the incidence of cervical carcinoma that the Netherlands has; a study of paraffin-embedded specimens detected 13 different HPV genotypes in the Surinamese group vs nine in the Dutch group. 8 This study shows that, for the diagnostic categories Negative, ASCUS, and SIL, a greater fraction of cervicovaginal smears will have detectable HPV hr in Surinam than in the Netherlands. This study also shows that, whereas Dutch and Surinamese Negative: ASCUS and Negative:SIL odds ratios differ, Dutch and Surinamese ASCUS:SIL odds ratios are quite similar. The results question the use of HPV DNA testing as a gold standard in general because the calculated sensitivity and specificity then become prevalence-dependent. The use of HPV DNA testing for creation of an ASCUS:SIL ratio, as previously suggested, is, however, supported. 5 In addition, a new statistic, the percent of negative smears with HPV hr , is posited, which may be very important in evaluating the clinical utility of HPV DNA testing.
Materials and methods

Case Selection
From a Dutch private cytology laboratory were obtained 300 000 consecutive pap smears; from a Surinamese screening program were obtained 10 000 pap smears. Both sets of smears received KOPAC system diagnoses, 9 which translate into Bethesda system classes: Negative (KOPAC S1), ASCUS (KOPAC S2-3), and SIL (KOPAC S4-9). The frequency distribution of diagnoses is displayed in 
Discussion
The fractions of Surinamese Negative smears, ASCUS smears, and SIL smears that had detectable HPV hr were greater than those of Dutch Negative smears, ASCUS smears, and SIL smears. The Negative:ASCUS and Negative:SIL odds ratios for the Netherlands differed from those in Surinam. The ASCUS:SIL odds ratio for the Netherlands was similar to that seen in Surinam.
Because Negative:ASCUS and Negative:SIL odds ratios in Surinam differed from those in the Netherlands, the sensitivity and the specificity of an abnormal cytologic examination cannot remain constant with respect to prevalence if HPV testing is used as the gold standard. This is also true because HPV infection and dysplastic/cancerous lesions do not bear a simple linear relationship. HPV infection is often transient in sexually active, young women with normal cervicovaginal cytology: in 93% of initially infected women, the same viral type was not detected upon re-examination four menstrual cycles later. 13 Heterogeneity is also supported by a meta-analysis of many studies from around the world that showed HPV types associated with cervical cancer varied by region.
14 Although HPV has been divided into high-and low-risk categories, studies evidence a wider array than previously thought of carcinogenic HPV serotypes. 15 Additionally, other cofactors in the carcinogenesis of this infection, such as smoking and bacterial flora, 16, 17 have been posited. In all, 80% of Surinamese smears without cytologic aberrations had detectable HPV hr ; 4% of Dutch smears without cytologic aberrations had detectable HPV hr . The bulk of the smears in both countries lack cytologic aberrations; were HPV DNA testing to be used as a gold standard, the sensitivity of an abnormal cytologic diagnosis would be considerably lower in Surinam than in the Netherlands. Similarly, because there is such a high background rate of HPV hr positivity in Surinam, the specificity of an abnormal cytologic diagnosis would of necessity be lower. Given that the pap smear is known to be an excellent screening tool in developing countries, 18 it follows HPV DNA testing is a questionable gold standard in general for cytology because if it were used the sensitivity and specificity would show variability independent of the judgment and ability of the person or laboratory who evaluates the smears.
Surinamese smears with detectable HPV hr have 3/4 the odds of receiving a Negative diagnosis from the person who reviewed the smears for this study as they would have of receiving an ASCUS diagnosis; the corresponding ratio for Dutch smears is 1/20. Over 80% of Surinamese ASCUS smears had detectable HPV hr . It follows that using HPV DNA testing to triage Surinamese patients with ASCUS diagnoses may expose a large fraction of these patients to unneeded colposcopy. The latter assertion should be empirically evaluated; if it is shown to be the case, the percent of Negative pap smears with detectable HPV hr should be determined before HPV DNA testing is used for purposes of ASCUS triage. When the percent of Negative pap smears with detectable HPV hr is very high, 80% for Surinam in this study, HPV testing is of questionable value in general.
Because the ASCUS:SIL odds ratios were the same for the Netherlands and for Surinam, it follows that the ASCUS:SIL odds ratio, in this study, was relatively independent of prevalence. This independence raises the possibility that the similarity of the ASCUS:SIL ratios of the two countries reflects differences in the assessment of abnormal smears. 5 The cause of such differences can be varied; no definite statements can be made without examining the histologic follow-up, which was not available for the Surinamese study. Because the ASCUS:SIL odds ratio was in this study prevalence-independent with respect to detectable HPV hr , the results support the ASCUS:SIL odds ratio as a quality control device, as previously described. 5 As noted, the ASCUS:SIL odds ratio must be accompanied by another measure or set of measures if it is to be interpretable. 5 By contrast, the fraction of ASCUS cases that have detectable HPV hr , which had been previously recommended as a quality control measure, 3,4 is probably not a good measure of diagnostic judgment in and of itself because, as this study shows, that fraction will vary for reasons that have nothing to do with the judgment of the cytologist. The conclusion that individual diagnostic categories show prevalence-dependence in regard to detectable HPV hr is supported by other studies. 5, 19, 20 In a retrospective study, two groups, one gold standard-positive, the other gold standard-negative, are evaluated by the test. Calculated directly are the sensitivity, specificity, and odds ratio. Knowing the test level permits estimates of predictive values. If the odds ratio changes when prevalence changes, sensitivity and specificity cannot be constant if prevalence changes.
In a prospective study, two groups, one testpositive, the other test-negative, are evaluated by the gold standard. Calculated directly are the predictive values and the odds ratio. Knowing prevalence permits estimates of sensitivity and specificity.
In a naturalistic study, one group is evaluated both by the gold standard and the test. Calculated directly are the fractions true positive (test-positive and gold standard-positive), false positive (test-positive and gold standard-negative), false negative (test-negative and gold standard-positive), and true negative (testnegative and gold standard-negative), as well as the odds ratio. 
